Near adult heights after growth hormone treatment in patients with idiopathic short stature or idiopathic growth hormone deficiency.
Determination of near adult height (NAH) after recombinant human growth hormone (rhGH) therapy in patients with idiopathic short stature (ISS, maximum stimulated growth hormone [MSGH] > 10 ng/ml) or idiopathic growth hormone deficiency (IGHD, MSGH < or = 10 ng/ml) enrolled in the National Cooperative Growth Study Substudy 2. Female NAH was defined as height at age 18 or age 14 plus Tanner stage 4; male NAH was defined as height at age 20 or age 16 plus Tanner stage 4 or 5. Both groups had similar enrollment heights: IGHD -2.7 +/- 0.7 versus ISS -2.8 +/- 0.6 (mean height standard deviation score [SDS] +/- SD). After rhGH treatment, there were no significant differences in NAH between the IGHD and ISS groups (-1.4 +/- 1.0 versus -1.6 +/- 1.0). Enrollment height SDS and MSGH value were significant predictors of delta height for the children with IGHD but not for the children with ISS (R2 = 0.45 IGHD versus R2 = 0.22 ISS). We conclude that MSGH values should not be used as the primary criterion for rhGH therapy.